There are many variables to consider when producing recombinant proteins, and more specifically recombinant antigens. These variables include expression system, purification techniques, protein tags, formulation, and assessment.
Proteos is an industry leader in the production of high-quality recombinant antibodies for drug discovery research. Here we will focus on the benefits of producing mAbs recombinantly in mammalian cells.
Recombinant Antibody Production: The Argument Against Hybridomas
1/26/2021
Proteos is an industry leader in the production of high-quality recombinant antibodies for drug discovery research. There are multiple methods for production of monoclonal antibodies, including hybridoma cell lines and recombinant protein technology. The following information will discuss some of the limitations of hybridoma production.
More than 6 million people worldwide are living with Parkinson’s Disease. Proteos has proudly partnered with The Michael J. Fox Foundation to provide high-quality protein reagents in support of Parkinson’s disease research.
Affinity tag placement is a crucial part of construct design
6/11/2020
Workflows for tackling challenging protein projects often utilize an affinity tag approach. Placement of the affinity tag is also an important decision that can influence protein expression, purification, and functionality.
During these uncertain times, we want you to know that Proteos’ labs are open and dedicated to providing critical research services. Partner with Proteos to advance your discovery research program.
Selecting the ideal affinity tag for your protein production project
4/21/2020
Workflows for tackling challenging protein projects often utilize an affinity tag approach. Selection of the proper affinity tag prior to project initiation can be challenging yet critical to the ultimate success of the project.
Proteos is committed to the health and safety of our employees, clients, and the community and will be taking actions to mitigate the risk of COVID-19 transmission.
